Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,580 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes (T1D) Clear all
Completed Not applicable Interventional Results available

Assessing Effectiveness of a Diabetes Navigator in Increasing Progression of Advanced Diabetes Technologies

NCT06229236
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Navigator
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 13, 2026, 5:48 PM EDT
Not yet recruiting Not applicable Interventional

Insul-In This Together: Leveraging Family Support and Diabetes Technology for Adolescents Living With Type 1 Diabetes

NCT07856836
View directory record Official record
Conditions
Diabetes Type 1
Interventions
Insul-In This Together
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
12 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2032
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 13, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes

NCT07090824
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Interventions
Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 13, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

Proleukin and Rapamune in Type 1 Diabetes

NCT00525889
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
IL-2, Rapamycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
New York, New York • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 13, 2026, 5:48 PM EDT
Not listed Phase 3 Interventional

Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study

NCT01067950
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Isolated Pancreas Transplant, Intensive Insulin Therapy
Procedure · Drug
Lead sponsor
Nantes University Hospital
Other
Eligibility
25 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2010 · Synced Oct 13, 2026, 5:48 PM EDT
Recruiting Not applicable Interventional

Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge

NCT06852950
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Type 1 Diabetes Mellitus (T1DM), Hyperglycemia
Interventions
Libre 3 Plus Continuous Glucose Monitor, Dexcom G7 Continuous Glucose Monitor
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 13, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients

NCT00791076
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo, Pancreatic Polypeptide (PP)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 13, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF)

NCT00999375
View directory record Official record
Conditions
Type I Diabetes
Interventions
Education, Problem Solving, Social Learning, Behavior Modification
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
8 Years to 17 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 13, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD

NCT01754259
View directory record Official record
Conditions
Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 13, 2026, 5:48 PM EDT
Terminated Not applicable Interventional

Camp Based Multi-component Intervention for Families of Young Children With Type 1 Diabetes

NCT04279587
View directory record Official record
Conditions
Type1diabetes
Interventions
Residential camp
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 5 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 13, 2026, 5:48 PM EDT
Recruiting Not applicable Interventional

Achieving Health in Emerging Adults With Diabetes (AHEAD) Program: A Clinical Trial Designed to Understand if Participation in a Clinical Program Developed Specifically to Support Emerging Adults With Type 1 Diabetes Leads to Improved Diabetes Outcomes.

NCT07292558
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes
Interventions
AHEAD Program
Behavioral
Lead sponsor
University of British Columbia
Other
Eligibility
16 Years to 19 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 13, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)

NCT02580877
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
67.5 mg oral insulin crystals daily, 500mg oral insulin crystals every other week
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 13, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

HAT in Eye Complications of Behcet's Disease

NCT00001865
View directory record Official record
Conditions
Behcet's Syndrome, Retinal Disease, Uveitis
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 13, 2026, 5:48 PM EDT
Completed Not applicable Interventional

School Centered Telemedicine Program for Children With Type 1 Diabetes Mellitus

NCT00566475
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
telemedicine
Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
5 Years to 14 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 13, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes With AID Use

NCT05204134
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Automated Insulin Delivery Settings Initialization and Adaptation Algorithm
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 13, 2026, 5:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

NCT01997411
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Nasal Glucagon, Intramuscular Glucagon
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
4 Years to 16 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 13, 2026, 5:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Imaging Inflammation in Autoimmune Diabetes

NCT00585936
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Oct 13, 2026, 5:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance

NCT04074668
View directory record Official record
Conditions
Diabetic Kidney Disease, Type 1 Diabetes, Diabetes, Diabetes Mellitus, Diabetes Complications, Diabetic Nephropathies, Type1diabetes, Diabetes, Autoimmune, Autoimmune Diabetes, Juvenile Diabetes, Type 1 Diabetes Mellitus
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams/milliliter (mg/ml), PET/CT Scan, Renal Biopsy
Drug · Radiation · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 13, 2026, 5:48 PM EDT
Recruiting No phase listed Observational

Twiist Postmarket Surveillance Study for Type 1 Diabetes

NCT07356089
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
Interventions
twiist Automated Insulin Delivery System
Device
Lead sponsor
Deka Research and Development
Industry
Eligibility
6 Years and older
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 13, 2026, 5:48 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

NCT07675590
View directory record Official record
Conditions
Health Adult Subjects, Obesity & Overweight
Interventions
TIX100, Placebo
Drug
Lead sponsor
TIXiMED, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 5:48 PM EDT
Active, not recruiting Phase 1 Interventional

Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen

NCT00706420
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Islet Transplantation + Immunosuppression, Islet cell transplantation
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 13, 2026, 5:48 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

NCT03260868
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 13, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)

NCT02074384
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Continuous Glucose Monitor, Self Monitoring Blood Glucose, Clinician
Device · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
7 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
New Haven, Connecticut • Tallahassee, Florida • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 13, 2026, 5:48 PM EDT
Active, not recruiting No phase listed Observational

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

NCT04598893
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Teplizumab, Placebo
Biological · Other
Lead sponsor
Provention Bio, a Sanofi Company
Industry
Eligibility
9 Years to 19 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Walnut Creek, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 13, 2026, 5:48 PM EDT